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Abstract
Purpose: We investigate a new heat delivery technique for the local treatment of solid tumors. The technique involves
injecting a formulation that solidifies to form an implant in situ. This implant entraps superparamagnetic iron oxide
nanoparticles (SPIONs) embedded in silica microbeads for magnetically induced moderate hyperthermia. Particle
entrapment prevents phagocytosis and distant migration of SPIONs. The implant can be repeatedly heated by magnetic
induction.
Methods: We evaluated heating and treatment efficacies by means of thermometry and survival studies in nude mice carrying
subcutaneous human colocarcinomas. At day 1, we injected the formulation into the tumor. At day 2, a single 20-min
hyperthermia treatment was delivered by 141-kHz magnetic induction using field strengths of 9 to 12mT under
thermometry.
Results: SPIONs embedded in silica microbeads were effectively confined within the implant at the injection site.
Heat-induced necro-apoptosis was assessed by histology on day 3. On average, 12mT resulted in tumor temperature
of 47.8C, and over 70% tumor necrosis that correlated to the heat dose (AUC¼ 282Cmin). In contrast, a 9-mT field
strength induced tumoral temperature of 40C (AUC¼ 131Cmin) without morphologically identifiable necrosis. Survival
after treatment with 10.5 or 12mT fields was significantly improved compared to non-implanted and implanted controls.
Median survival times were 27 and 37 days versus 12 and 21 days respectively.
Conclusion: Five of eleven mice (45%) of the 12mT group survived one year without any tumor recurrence, holding promise
for tumor therapy using magnetically induced moderate hyperthermia through injectable implants.
Keywords: Magnetic induced hyperthermia, superparamagnetic nanoparticles, implant, precipitating polymers, subcutaneous
xenograft, necrotizing colocarcinoma, survival, thermometry
Introduction
Hyperthermia, the therapeutic application of heat,
has revealed large benefits in oncology. Moderate
hyperthermia (resulting in tissue temperatures of 40
to 46C) is associated with cytotoxic protein desta-
bilization and denaturation. Cellular defense against
heat consists in reactions favoring tolerance to heat
stress, closely correlated with the induction of heat
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shock proteins. This tolerance is inhibited above
the temperature threshold of about 42C and the
result is in a pronounced increase in cell death
rate [1]. Moderate hyperthermia turns the vascular
deficiency of a tumor to therapeutic gain by taking
advantage of relative enhanced sensitivity to heat
damage. A variety of reference therapies in oncology
– namely, radiotherapy, brachytherapy, chemother-
apy or a combination thereof – have been synergis-
tically combined with moderate hyperthermia [2, 3].
The outcome of a hyperthermia treatment corre-
lates to the heat dose administered [4], which, in
turn, is dependent upon anatomical situation
and heating modalities. Local hyperthermia aims to
confine heat delivery to the lesion site. Despite steady
improvements in heating localization of external
or interstitial modalities based on standard heat
application means (radiofrequencies, microwaves
and ultrasounds), physical limitations still hinder
the treatment of deep-seated lesions [5]. Power
transmission in the case of acoustic or electromag-
netic waves is limited by the reflection and absorp-
tion of power into tissue and interstitial liquid.
In contrast, magnetic fields can cross the diamag-
netic body of a patient without losses. Monodisperse
superparamagnetic iron oxide nanoparticles
(SPIONs) exposed to alternative magnetic fields
(AMFs) convert the magnetization energy into
heat. This scales as P/H2f 2 where P is the power
loss, H the AMF amplitude and f the frequency
[6, 7]. The rate of heat generation is larger than for
metallic implant such as seed [8]. Magnetic fluid
hyperthermia [9], i.e. heating interstitially injected
SPIONs through alternating magnetic induction,
has also shown promising clinical results [10–13].
One drawback of current administration techniques
is that SPIONs fade ineluctably out from the
injection site into the lymphatic and blood circula-
tion or are sequestrated in macrophage, exposing
patient to potentially toxic hazards [14].
We report here the feasibility of an original
approach of magnetically induced local moderate
hyperthermia through an in situ-formed implant that
traps SPIONs embedded in silica microbeads. After
injection in aqueous environment and precipitation
from their organic solvent formulation, water-inso-
luble polymer chains entangle and form a matrix
holding the dispersed superparmagnetic microbeads.
SPIONs are hence protected and durably confined
at the injection site, avoiding their phagocytosis and
distant migration. The opportunity to repeat implant
heating in the long term as necessary could also offer
therapeutic benefits. We performed thermometry
and survival studies in a model of human colocarci-
noma tumor that was subcutaneously engrafted
in nude mice. Our goal was to assess heating
efficiency and treatment potential of local moderate
magnetically induced hyperthermia delivered
through the implant formed in situ.
Materials and methods
Magnetics beads
We used silica particles containing 32% w/w of
nanometric iron oxide particles of 10-nm mean
diameter. The micron-sized particles had a density
of 2.12 0.02 gcm3 at 25C. They were synthe-
sized as described by Chastellain et al. [15]. Briefly,
tetramethoxysilane (45mL) was added to a 2M
solution of Fe(NO3)3  9H2O in ethanol (44.4 g iron
salt in 55mL ethanol). The mixture was stirred
vigorously for 10min, transferred to a sealed glass
container and allowed to gel at 50C. The obtained
brown gel was ground and separated by sieving.
Particles smaller than 100mm were thermally treated
at 500C for 24 h, followed by high-energy attrition
milling for 1 h. Measurements using a superconduct-
ing quantum interference device (SQUID) con-
firmed superparamagnetic properties. The specific
absorption ratio (SAR), which reflects the heating
capacities, is conventionally defined as the slope of
the initial temperature rise multiplied by the specific
heat capacity. In our case, this was in the order
of 18W/g iron oxide for a 12-mT magnetic field.
The volume median diameter of the silica beads
containing the iron oxide was determined on a
Malvern Mastersizer as (D(v, 0.5))¼ 0.9 mm. The
sizes of the magnetic iron oxide nanoparticles as
established by transmission electron microscopy
(TEM), X-ray diffraction (XRD), and zero-field
cooled magnetic measurements were 9 1 nm,
11.3 1nm and 15.5 1.3 nm, respectively.
Injectable formulation
The ethylene vinyl alcohol copolymer EVALTM
105-B (EVAL Europe, Zwijndrecht, Belgium) was
dissolved at 8% (w/v) in pharmaceutical grade
dimethyl sulfoxide (DMSO) (Gaylord Chemical
Corp., Los Angeles). Using ultrasound and vigorous
mechanical stirring, the beads were suspended at
40% (w/v) in the resulting polymer solution. The
preparation was finally sterilized by 15min auto-
claving at 121C. As flocculated sedimentation
occurred during storage, energetic shaking restored
suspension homogeneity before use. Based on
pycnometric measurements and calculations, the
resulting density of the formulation was in the
order of 1.26 gcm3.
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Alternating magnetic field generator
The field generator used (TIG 2.5, Hu¨ttinger
Elektronik, Freiburg, Germany) consisted of an
alternating current generator feeding the coil induc-
tor (internal, external diameters and length of the
horizontal coil were 54, 64 and 46mm respectively).
A conical tube mouse restrainer was introduced
within the coil so that the implanted tumor was
positioned at the center. With a small pick-up coil
calibrated using a teslameter we found a linear
relationship between the magnetic field amplitude
at 141 kHz and the generator peak-to-peak voltage.
Current intensity was adjusted to impose the voltage
corresponding to the chosen field strength.
Tumor model
Tumors generated by subcutaneous injection of the
human Co112 colon carcinoma cells were main-
tained by serial subcutaneous transplantation in
Swiss nude mice [16]. About 15mm3 of excised
and minced tumor was subcutaneously engrafted
into the right flank of 5-week-old Swiss nude mice
and the nodule was allowed to grow for 4 to 6 weeks.
We determined the volume of the tumor (Vtum) by
measuring with calipers three tumor dimensions:
length (l), width (w) and thickness (t) and using the
following formula: Vtum ¼ 1=2ðlwtÞ [17], with an
uncertainty of 15%. Care was taken to implant
the tumor above hind leg musculature in order to
avoid detrimental heat exposure of intestinal tissues.
The obtained tumor showed peripheral angiogenesis,
necrosis in the tumor center core and a pseudocap-
sule composed of connective tissue. Central necrosis
is a common feature in Co112 tumors, also observed
in in vitro-grown multicellular spheroids and liver
metastases [18].
Mice
One-month-old female Swiss nude mice were sup-
plied by Charles Rivers (Iffa Credo, Saint Germain
sur l’Arbresle, France). Animal experiments were
performed according to the ethical principles of
laboratory animal care and Swiss legislation.
Experiments were specifically approved by the official
committee of animal research surveillance of the local
authority. Animals were maintained in SPF animal
house under a 12 h light and 12 h darkness cycle with
normal diet, ad libitum, respecting a maximum of
five animals per cage. Animals were euthanized by
asphyxia under CO2 saturated atmosphere.
Implantation
We set the injection volume to 0.25mL (i.e. 84.1mg
of magnetic microparticles or 26.9mg of iron oxide)
to ensure that the intra-tumoral implant mass would
be sufficiently large to heat the entire tumor. This
injection volume was as large as or slightly larger than
the tumor volume. The DMSO dose injected
was below the mouse intraperitoneal LD50 (13 g/kg)
[19]. The formulation was slowly injected over
a 1-2min period into the tumor through a 22G
needle. Systemic and local toxicities were limited.
Thanks to the brownish color and stiffness of the
implant, we could manage and verify correct
implant distribution by observing tissue darkening
and induration. The implant first entered into the
necrotic core and then extended towards the
surrounding pseudocapsule to reach the peripheral
border of the tumor. To avoid distant leakage, we
paid special attention to needle positioning, in order
to distribute the implant uniformly without accumu-
lation in a part of the nodule. The procedure gave
rise only to transient perinodular edema, which was
spontaneously resorbed by the time we proceeded to
alternating magnetic field stimulation.
Thermometry
We monitored temperature with a fluoroptic thermo-
meter (Luxtron, Santa Clara, CA) using three
fiber optic probes of 200 mm diameter. The device
reported temperatures once a second with
0.1C accuracy. A one-point calibration at
20.0C was performed before each experiment.
Data were acquired using Physitemp software
(Luxtron).
In vivo investigation protocols
Thermometry studies: 0.25mL of the 8% (w/v) EVAL
solution in DMSO containing 40% (w/v) microbeads
was injected into each mouse tumor (day 1). After
24 h, the animal was exposed to a 20-min alternating
magnetic field (141 kHz), under halothane-induced
general anesthesia (day 2). We investigated five
magnetic field strengths: 9, 10, 10.5, 11 and 12mT
with respectively n¼ 5, 3, 6, 3 and 5 animals per
group. Temperatures were monitored in the tumor,
on the skin over the tumor, and in the hollow of the
brachial plexus. The animals were sacrificed 24 h
later (day 3) for standard histology. Tumor size in the
animals used for thermometry studies was in the
range of 0.1 to 0.3 cm3.
Survival studies: For the survival investigation
protocol, we injected 0.25mL of 8% (w/v) EVAL
solution in DMSO containing 40% (w/v) beads
(day 1). After 24 h, animals were exposed to an
alternating magnetic field (141 kHz) for 20min
(day 2). Two thermometry probes were affixed to
the skin over the tumor, and one was fixed over
the brachial plexus. Animals were sacrificed when the
Local hyperthermia by magnetic implant in mouse 231
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tumor volume reached ten times the initial volume.
We investigated four groups: control with neither
implant nor magnetic field (n¼ 6), implanted control
(no magnetic field) (n¼ 7), 10.5mT treated (n¼ 7),
and 12mT treated (n¼ 11). Animals were assigned
to different treatment and control groups in order to
ensure similar mean tumor sizes: the respective mean
initial tumor size and standard deviations were
59 (54) mm3 for the control group, 52 (44)
mm3 for the implanted control group, 53 (33) mm3
for the 10.5-mT treated group and 64 (42) mm3 for
the 12-mT treated group. In a multigroup compar-
ison, tumor size in the different groups was indeed
shown to be very similar (Friedman test: p40.8).
Histology
The tumors and part of the surrounding tissues
(overlying skin and adjacent muscle fascia or
peritoneum) were fixed in buffered neutral formalin
(1 : 10). Slices 3mm thick were embedded in paraffin
(through alcohol dehydration and xylol clearing),
and 5mm thick sections were stained with hematox-
ylin and eosin. The ratio of necrotic tumor to whole
tumor volume was semi-quantitatively scored from
0 to 100%. Microphotography was performed with
a Nikon eclipse E800 microscope (Olympus Corp.,
Center Valley, USA) and histomorphometry using
ImageJ 1.38x software (National Institutes of Health,
USA).
Imaging
For magnetic resonance imaging we used a MRI
scanner (Achieva 1.5T, Philips, Eindhoven, the
Netherlands). For micro-computerized tomography,
we used a Micro-CT scanner (Skyscan 1076,
Kontich, Belgium).
Statistics
StatView version 5.0 software ( SAS Institute Inc.)
was used for statistical analysis. Statistical signifi-
cance was considered at p< 0.05. For the thermo-
metry study we used the Kruskall-Wallis test,
the Mann-Whitney U test and the Spearman
correlation test. For the survival studies we employed
the Friedman test and Kaplan Meyer analysis.
Results
Precipitation of the injectable formulation fills the
initially necrotic core and peripheral extensions
of the tumor
Injection of the formulation was accompanied by
mild acute toxicity [20, 21]. The injected 0.25-mL
volume in a 25-g mouse would translate to 700mL in
a 70-kg patient, representing indeed a large injection
volume per body weight. Systemic manifestations,
most probably due to DMSO, consisted of transient
fatigue and ocular irritation with eyelid ptosis.
Locally, we observed edematous dilatation of the
tumor site. Edema was rapidly reversed along with
solvent clearance. Afterwards, the implanted tumor
when recovered was shown to have dimensions larger
than the initial tumor.
As previously observed in other experiments,
Co122 tumors showed extensive central necrosis
(up to 50%) [22]. Similar necrotic centers have been
observed in Co112 multicellular spheroids grown
in vitro [23]. Under electron microscopy, the Co112
tumor spheroids developed junctional complexes
and desmosomes, while oxygen measurements had
shown severe central hypoxia [24]. Histology con-
firmed that the implant was invariably present in the
necrotic tumor core and extended towards the viable
peripheral rim of cells. We did not observe an
inflammatory response in either the control or the
implanted control groups, sacrificed one day after
injection (Figure 2a). Occasionally an implant
extension had leaked into peritumoral loose con-
nective tissue, mostly in the case of small and vital
tumors. To assess implant distribution, we quantified
the percentage of the implant that was in contact with
stromal tissue (Table I) and found correlation only
with the initial tumor volume (Spearman ¼ 0.645;
p¼ 0.0412), not with thermometry parameters.
Entrapment of microbeads within the implant
polymer network was confirmed through use of
the Prussian Blue stain, which identified iron
Table I. Summary of parameters (meanSD) calculated for each group of the thermometry study for 5 magnetic field
strengths.
Field strength (mT) 9 (n¼ 5) 10 (n¼ 3) 10.5 (n¼6) 11 (n¼ 3) 12 (n¼ 5)
Initial tumor volume (mm3) 217 254 122 38 119 82 279 60 220 104
Implant that is in contact with stromal tissues (%) 67 39 55 38 72 12 60 30 50 19
Tumor ET (C) 40.0 3.1* 42.5 3.7 42.9 2.3§ 43.5 1.6y 47.8 2.2*§y
Tumor AUC (Cmin) 131.1 44.3* 168.8 47.8§ 183.4 39.9y 183.8 34.0jj 282.5 40.0*§yjj
Skin ET (C) 38.6 3.0*y 42.4 4.0 42.0 2.0§y 43.5 2.0jj 48.4 2.0*§jj
Tumor necrosis (%) 67 25 56 15 60 25 52 13 78 6
The U Mann-Withney test was used to evaluate statistical significance between the groups of mice. *p< 0.001, §yjj p< 0.05.
232 P.-E. Le Renard et al.
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oxide nanoparticles. In vitro, bare SPIONs of nano-
scale size were also efficiently trapped by this network.
A preliminary formulation study with a batch of
finer sub-micrometer beads confirmed entrapment
efficiency but resulted in poor syringeability and
an inadequate implant distribution pattern.
The implant formed in situ can heat the tumor by
magnetic induction at 141 kHz across the whole
temperature range of moderate hyperthermia as
a function of field strength
Thermograms consistently exhibited a similar shape
(Figure 1a). After a steep increase during the first
5min, temperatures reached a plateau corresponding
to an equilibrium between implant heat production
and dissipation through diffusion and convection.
The observed plateau temperature was not due to
a diminishing response capacity of the superpara-
magnetic beads, since stepwise field increase in a
separate experiment had produced stepwise increas-
ing temperatures throughout the 25-min exposure
period (Figure 1b). To obtain a parametric value
of this equilibrium, we defined the equilibrium
temperature (ET) as the averaged temperature over
the final 15min of magnetic field application. Table I
shows that the mean tumor site ET increased with
magnetic field strength (Spearman ¼ 0.724;
p< 0.001). We observed the lowest mean tumor
site ET (40C) for the group treated with the lowest
magnetic field strength, i.e. 9mT (Table I).
Treatments with intermediate magnetic field
strengths of 10 to 11mT led to intermediate mean
Figure 1. Thermograms representing tumor temperature as a function of time. (a), during single 20-min treatments in a
141KHz alternating magnetic field, for magnetic field strengths of 9mT (n¼ 5), 10mT (n¼ 4), 10.5mT (n¼ 5), 11mT
(n¼ 3), 12mT (n¼ 5). (b), during two stepwise 25-min treatments in an 141-KHz alternating magnetic field. Magnetic field
strength was 9mT from 0 to 10min, 10mT from 10 to 15min, 11mT from 15 to 20min, 12mT from 20 to 25min.
Local hyperthermia by magnetic implant in mouse 233
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values of tumor site ET between 42.5 to 43.5C that
were not statistically different. For the group treated
with 12-mT magnetic field, the mean tumor site ET
of 47.8C was significantly larger than for all other
magnetic field strengths.
The area under the curve (AUC) of temperature as
a function of time is a parameter related to the heat
dose delivered during a given treatment [25, 26]. For
the group treated with the highest magnetic field
strength (12mT), we recorded a more than two-fold
increase in mean AUC (282.5Cmin) as compared
to the group treated with 9mT (131.1Cmin).
Mean AUCs for intermediate magnetic field strengths
of 10 to 11mT were again intermediate (Table I).
When considering the entire range of investigated
magnetic field strengths, AUC was positively corre-
lated with the 5 different magnetic field strengths
applied (Spearman ¼ 0.739; p< 0.001).
Above a threshold temperature, a larger delivered heat
dose increases the extent of induced necro-apoptosis
to whole tumor
The necrosis to tissue ratio, as quantified using
histology, was not significantly different between
injected and non-injected controls, suggesting that
the implant itself does not induce necrosis. We
assessed the heating efficiency microscopically
in terms of coagulation necrosis of vital tumor and
adjacent tissues. In the case of low heat delivery, the
extent of spontaneous and heat-induced necrosis
Figure 2. Microphotographs at D2 (with or without implant injection at D0 and hyperthermic treatment at D1). Panel (a)
shows at left the control Co112 tumor, with non-induced necrosis (arrow) that typicaliy did not exhibit an inflammatory
reaction (insert), and at right the control with the nonheated implant shown in brown. Panel (b) displays three treated
tumors at low magnification in the upper row and at higher magnification in the lower row. On the left, a tumor treated with
a magnetic field strength of 10 mT (MET¼ 39.5C, AUC¼ 152.8¯C1min) leaving most of viable tumor tissue (T) without
any heat-induced necrosis. In the middle, a tumor treated with a magnetic field strength of 10.5 mT (MET¼ 44.0C,
AUC¼ 211.8C1 min) shows clear heat-induced necrosis (h) around the implant, but more distant tumor tissue remains
viable. On the right, a tumor treated with a magnetic field strength of 12 mT (MET¼ 46.2C, AUC¼ 284.3C1 min)
illustrates heat induced necrosis (h) covering most of the tumor and effecting intense thermal damage (H) in the vicinity of
implant, accompanied by an inflammatory reaction (neutrophils and macrophages, see insert). Panel (c) illustrates the
topographic association between implant and heat-induced necrosis. A small isolated extension of the implant (arrow) did
not trigger heat damage, in contrast to the more voluminous main body of the implant.
234 P.-E. Le Renard et al.
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overlapped. However, the extent of the necrosis was
quite different between moderately and intensively
heated tumors. Figure 2b shows heat-induced
damage patterns for three tumors treated at magnetic
field strengths of 10, 10.5 and 12mT, respectively.
For treatments associated with temperature higher
than 44C we observed extensive tumor necrosis and
coagulation necrosis. In the vicinity of the implant,
we observed an inflammatory infiltrate of neutrophils
and macrophages as part of non-specific immune
response to necrosis. Focal necrosis of the immedi-
ately adjacent connective and muscle tissues can be
attributed to heat, since this was absent in mice
injected with implant alone or at lower heating
levels. Likewise, the skin, especially over the
implanted tumor, showed heat-induced necrosis.
In some animals, muscle tissue at the peritoneal
side of the tumor showed signs of thermal damage.
For treatments reaching less than 42C, no signifi-
cant heat-induced necrosis was observed. Notably,
heat-induced necrosis was not observed in implanted
mice exposed to the magnetic field strength of 9mT
and was only occasionally found in mice exposed
to 10 or 10.5mT, clearly depending on heating
intensity. It was found that AUC was well correlated
with heating efficiency at the tissue level, quantified
in terms of the percentage of tumor necrosis
(Spearman ¼ 0.468; p< 0.05).
Magnetically induced heat delivery through an
implant is highly efficient in treating solid tumor for
a magnetic field strength of 12mT
In groups of animals matched for tumor size,
magnetically induced heating of the implant pro-
longed survival time as defined by growing to
10 times the initial tumor size. After a single
20-min treatment, a median survival time of
27 days was observed for the group treated with
a magnetic field strength of 10.5mT (Figure 3).
Median survival time increased further to 37 days for
mice treated with 12mT, as compared with 12 days
for non-implanted controls and 21 days for
implanted controls. Finally, only one complete
response was observed in the 10.5mT group, while
5 of 11 animals (45%) treated with 12mT exhibited
complete responses that persisted until the one-year
mark, when mice were sacrificed. Kaplan-Meyer
analysis revealed significant differences between the
10.5-mT treated group and the non-implanted
control group ( p< 0.05), while the 12-mT treated
group was significantly different when compared to
the implanted and non-implanted controls ( p< 0.05
and p< 0.01, respectively).
Computerized tomography allows for precise
implant imaging
We studied implant precipitation pattern in vivo
using magnetic resonance imaging (MRI) and
computerized tomography (CT) of two implanted
and non-treated mice. In MRI, silica-embedded
SPIONS led to a susceptibility artifact, partially
masking the implanted tumor (Figure 4a). We
confirmed entrapment of the beads at the injection
site through the absence of distant artifacts.
In contrast, micro-computerized tomography
allowed detailed imaging of the implant, confirming
intra-tumor precipitation pattern of the implant
(Figure 4b). Image contrast was set in the bone
density range to ensure proper imaging of the high-
density implant, albeit masking soft tissues.
Figure 3. Survival curves. Dotted line: control group (c), n¼ 6; dashed line: implanted control group (IC), n¼ 7 normal
line: 10.5-mT treated group, n¼ 7; bold line 12-mT treated group, n¼ 11. Note that in the group treated with a 12-mT
alternating magnetic field, 5 of 11 mice survived 12 months after treatment without tumor relapse.
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Randomly distributed density measurements
(n¼ 100) recorded in the implant volume suggested
a relatively homogeneous iron distribution, with a
variation coefficient of 10% over the whole implant.
Discussion
Our results show the feasibility of implant-mediated
hyperthermia using an injected formulation of
superparamagnetic beads that solidifies upon contact
with interstitial fluid.
A gradual injection gave sufficient time for the
formulation to spread into the tumor before sub-
sequent precipitation and solid implant formation
in situ. The tumor necrotic center was initially filled,
and the precipitation subsequently extended towards
the peripheral tumor spaces. Although attractive, the
concept of an implant layer in contact with the outer
tumor rim, where vital cancer cells are found, seems
impractical due to the dense heterogeneous tissue
surrounding the tumor core. In the absence of
image guidance, tumor core injection led to a more
controlled implantation. This last step was critical
with regard to eventual occurrence of leakage. The
implant volume was constrained in situ to match the
tumor volume. The injection volume of 0.25mL was
acceptable even if it was larger than initial tumor
volume. This is partly explained by implant mass
loss following diffusion and exchange of DMSO with
water (16%), and partly by tumor distension
following implantation and edema resorption.
Similar formulations without magnetic particle have
shown in preliminary ex vivo experiments [27], that
implant volume was constant in situ and that the
DMSO solvent most likely induced tissue swelling.
Noteworthy, the resulting viscoelasticity of such
formulation, as in the case of bone cements, can
lead to overestimation of the injected volume due
to contraction. This can also be associated with
needle withdrawal before complete flow arrests, as
well as with compositional variations following filtra-
tion through reversible particle aggregates [28, 29].
The implant was localized at the center of the tumor
but it did extend into peripheral layers. This was
particularly appropriate for magnetically induced
delivery of heat produced by the entrapped super-
paramagnetic micron-sized particles. This entrap-
ment was very efficacious and we never observed
particles outside the tumor volume under multiple
orthogonal techniques (histology, CT and MRI).
We also attempted to use smaller particles, including
sub-micrometer silica beads and 20-nm bare
SPIONs. We observed efficient entrapment in the
precipitated polymer network, but, with these smaller
beads, the preparation resulted in rheological beha-
vior that was prone to leakage.
In a clinical scenario, the application of AMF
could lead to safety concerns. The side effects of
AMF can include non-specific heating outside the
target volume due to the magnetic induction of
current density called eddy currents (EC) [30]. More
problematic is the case of radiofrequencies [31], for
which adverse excitation of neurons can be easily
triggered by induced electric fields. Heat produced
by EC, scaled as: SAREC/ (H  f )2r2, where SAR is
the specific absorption rate (W/g tissue), and r is the
Figure 4. Implant imaging. (a), MRI imaging of a swiss
nude mouse bearing a subcutaneous tumor injected with
0.25ml of the implant formulation, with a T1 weighted
sequence. The tumor zone is enclosed in the dotted white
circle, highlighting the susceptibility artifact caused by
SPION entrapped in the implant. (b), Micro-computerized
tomography of a swiss nude mouse bearing a subcutaneous
tumor punctured with 0.25ml of the implant formulation.
In the transversal, section, we can precisely localize the
implant (in white) and the tumor that is enclosed within
the dotted black circle. The SPIONs entrapped in the
implant allowed for X-ray absorption with an absorption
density close to that of bone (see, for instance, the spinal
vertebrae and iliac wing highlighted by the dotted white
circle). Note that the window is adjusted for bone density
without further soft tissue contrast refinements or the use
of contrast agent.
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radius of exposed region [32], can lead to distant
painful hot spots that would limit the values of f
and H, and thus the heating possibilities. The AMF
used here is associated with (H  f ) values ranging
from 10108 to 13.5108A/(ms) for 9mT (7.2 kA/m)
and 12mT (9.6 kA/m), at 141 kHz. These fields did
not induce any directly measurable effect in control
mice that had not received any implant. Accordingly,
we believe that this approach would be entirely
appropriate for human [33]. In the case of AMF
treatment of prostate cancer, the pelvic skin fold is at
particular risk of hot spot triggered by EC. However
values of (H  f ) up to 5108A/(ms) were safe for
100% of the patients [34, 35]. As for AMF treatment
of glioblastomas, no side effects were reported during
skull exposition for (H  f ) values up to 13.5108A/
(ms) [36]. (H  f ) values higher than 20108A/m/s
have been used in and ex vivo [37, 38]. Pulses of very
high amplitude have been experimentally used in
mice [32].
The investigated 9- to 12-mT field strengths
induced a tissue temperature rise from mild
hyperthermia in the range of 39–42C extending
to cytotoxic moderate hyperthermia in the range of
42–48C. Treatments at higher temperatures were
associated with extensive tumor necrosis and collat-
eral damage mainly to adjacent skin. It is worth
mentioning that the tissue origin is of importance:
mouse tissues are more sensitive to heat than the
human tissues used here in form of the human tumor
transplant.
Under alternating magnetic field induction, the
measured skin temperatures were generally less than
intra-tumor temperatures, so long as heating
remained at non-toxic levels. However, on reaching
toxic heat levels, the skin temperature rose to intra-
tumoral levels (see Table I). These observations
underline the importance of cooling by tissue
perfusion [39, 40]. When skin blood perfusion
breaks down as a consequence of heat damage to
the vasculature, the cooling effect of blood perfusion
stops and skin temperature raises to a value close
to the tumor temperature.
The extent of heat-induced necrosis seemed to be
related to the manner of implant distribution in situ.
Thus, around extensions that were confluent or of
large cross-section, necrosis was wider than around
thin implant extensions (Figure 2c). It is likely
that the latter delivered less heat to surrounding
tissues [41]. Certainly, this could result from
a combination of different factors: first, a threshold
mass for dissipating significant heat [42] from the
implant center to distant tissue areas, and, secondly,
a differential effectiveness in vascular cooling [43].
Indeed, since cooling efficiency is directly related to
the contact area between implant and tissue, whereas
heating power is proportional to implant mass,
small implants that present a higher surface/mass
ratio will be more efficiently cooled. Measurement
of the necrosis rim width in biologically relevant
implants as well as in vitro or in vivo thermal
mapping studies indicated a necrosis extent in the
order of 2–3mm, compatible with previously pub-
lished observations [44].
Our survival study revealed an important thera-
peutic potential for a single 20-min treatment based
on the sole cytotoxicity of hyperthermia. We
observed a minor growth delay in the group that
received the implant but was not submitted to
magnetically induced heating. Although we cannot
fully exclude local toxicity of DMSO, this growth
delay is more likely due to implant precipitation in
capillaries and secondary hemostasis, leading to
antineoplastic effects through hypoxia. Magnetically
induced hyperthermia treatment, however, did
increase significantly the median survival time.
A number of definitive complete responses were
observed at a rate that depended on the magnetic
field amplitude. It is well known that temperature
distribution in tumor is essential to assessing treat-
ment responses [45]. This distribution is directly
related to magnetic field strength and implant
localization, and its control depends on thermometry
data. The suboptimal heating of peripheral tumor
cells allows for a tumor relapse when tissue escapes
the cytotoxic area of the temperature gradient.
In comparison to the 10.5-mT single 20-min
treatment, these considerations suggest that one
might achieve a better outcome by increasing the
magnetic field strength to 12mT.
A survival study using imaging techniques could
address the important issue of implant distribution.
It would allow controlled injection of the implant
and, if necessary, exact localization of thermometry
probes. Clinically, imaging could allow a control of
the correct implant size and localization to further
improve or predict heat delivery. While MRI
appeared most sensitive to the presence of the
superparamagnetic beads, leading locally to some
artifacts, CT was most appropriate for implant
imaging without any obvious artifacts in its vicinity.
Furthermore, soft tissue contrast agent would allow
studies of intratumoral implant distribution.
Regarding the implant durability, we retrieved
intact implants as expected at day 14, but we
observed partial degradation at day 48 in two treated
mice. No implant or tumor was macroscopically
observable after the one year survival period. These
sparse data points suggest that unexpected degrada-
tion occurs after a few months. The high solid
fraction may account for loss of implant strength,
and the heating process may accelerate focal inflam-
matory events. These observations warrant further
investigations into the distribution and metabolism
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pathways of iron in the implants, compared to
SPIONs, free or embedded in silica beads.
In conclusion, these results demonstrate the effi-
cacy of superparamagnetic particles embedded in
an in situ formed implant to deliver thermal energy
in a therapeutically relevant range [46]. Sustained
moderate hyperthermia at clinically relevant field
strengths were produced in a necrotizing tumor
model, holding promise for implant-mediated local
hyperthermia therapy.
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